199 related articles for article (PubMed ID: 29680373)
1. [Fluindione and falciparum malaria treated by atovaquone-proguanil].
Kamaliddin C; Joste V; Argy N; Houzé S
Therapie; 2018 Oct; 73(5):445-447. PubMed ID: 29680373
[No Abstract] [Full Text] [Related]
2. Erythema multiforme and Malarone(®).
Becher G; Wylie G
Travel Med Infect Dis; 2012 Sep; 10(5-6):279-80. PubMed ID: 22951669
[No Abstract] [Full Text] [Related]
3. [Atovaquone-proguanil treatment failure in Plasmodium falciparum].
Contentin L; Grammatico-Guillon L; Desoubeaux G; Baron S; Thanh HD
Presse Med; 2011 Nov; 40(11):1081-3. PubMed ID: 21570798
[No Abstract] [Full Text] [Related]
4. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).
Boggild AK; Parise ME; Lewis LS; Kain KC
Am J Trop Med Hyg; 2007 Feb; 76(2):208-23. PubMed ID: 17297027
[TBL] [Abstract][Full Text] [Related]
5. Atovaquone and proguanil hydrochloride for treatment of malaria.
Kremsner PG; Looareesuwan S; Chulay JD
J Travel Med; 1999 May; 6 Suppl 1():S18-20. PubMed ID: 23573548
[TBL] [Abstract][Full Text] [Related]
6. Atovaquone and proguanil hydrochloride for prophylaxis of malaria.
Shanks GD; Kremsner PG; Sukwa TY; van der Berg JD; Shapiro TA; Scott TR; Chulay JD;
J Travel Med; 1999 May; 6 Suppl 1():S21-7. PubMed ID: 23573549
[TBL] [Abstract][Full Text] [Related]
7. [Value of malarone in therapy of malaria tropica].
Ziegler T; Schau A; Winkler C
Med Klin (Munich); 2002 Aug; 97(8):455-8. PubMed ID: 12229244
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.
Sutherland CJ; Laundy M; Price N; Burke M; Fivelman QL; Pasvol G; Klein JL; Chiodini PL
Malar J; 2008 Nov; 7():240. PubMed ID: 19021900
[TBL] [Abstract][Full Text] [Related]
9. Atovaquone-proguanil chemoprophylaxis in the era of Tafenoquine.
Meltzer E; Schwartz E
J Travel Med; 2019 Jun; 26(4):. PubMed ID: 30535377
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan.
Hitani A; Nakamura T; Ohtomo H; Nawa Y; Kimura M
J Infect Chemother; 2006 Oct; 12(5):277-82. PubMed ID: 17109092
[TBL] [Abstract][Full Text] [Related]
11. WITHDRAWN: Drugs for preventing malaria in travellers.
Jacquerioz FA; Croft AM
Cochrane Database Syst Rev; 2015 Oct; (10):CD006491. PubMed ID: 26436859
[No Abstract] [Full Text] [Related]
12. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.
Høgh B; Clarke PD; Camus D; Nothdurft HD; Overbosch D; Günther M; Joubert I; Kain KC; Shaw D; Roskell NS; Chulay JD;
Lancet; 2000 Dec; 356(9245):1888-94. PubMed ID: 11130385
[TBL] [Abstract][Full Text] [Related]
13. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.
Looareesuwan S; Chulay JD; Canfield CJ; Hutchinson DB
Am J Trop Med Hyg; 1999 Apr; 60(4):533-41. PubMed ID: 10348225
[TBL] [Abstract][Full Text] [Related]
14. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
McKeage K; Scott L
Drugs; 2003; 63(6):597-623. PubMed ID: 12656656
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.
Nakato H; Vivancos R; Hunter PR
J Antimicrob Chemother; 2007 Nov; 60(5):929-36. PubMed ID: 17848375
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic and oxidative status of human lymphocytes after exposure to clinically relevant concentrations of antimalarial drugs atovaquone and proguanil hydrochloride in vitro.
Dinter D; Gajski G; Domijan AM; Garaj-Vrhovac V
Fundam Clin Pharmacol; 2015 Dec; 29(6):575-85. PubMed ID: 26434663
[TBL] [Abstract][Full Text] [Related]
17. Drugs for preventing malaria in travellers.
Jacquerioz FA; Croft AM
Cochrane Database Syst Rev; 2009 Oct; (4):CD006491. PubMed ID: 19821371
[TBL] [Abstract][Full Text] [Related]
18. Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone-proguanil in traveller returning from Congo.
Massamba L; Madamet M; Benoit N; Chevalier A; Fonta I; Mondain V; Jeandel PY; Amalvict R; Delaunay P; Mosnier J; Marty P; Pomares C; Pradines B
Malar J; 2020 Jan; 19(1):37. PubMed ID: 31964401
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.
Na-Bangchang K; Manyando C; Ruengweerayut R; Kioy D; Mulenga M; Miller GB; Konsil J
Eur J Clin Pharmacol; 2005 Sep; 61(8):573-82. PubMed ID: 16041597
[TBL] [Abstract][Full Text] [Related]
20. Atovaquone/proguanil for plasmodium falciparum malaria.
Sehdev PS
Pediatr Infect Dis J; 2002 Aug; 21(8):787-9. PubMed ID: 12192170
[No Abstract] [Full Text] [Related]
[Next] [New Search]
